Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atazanavir + rosiglitazone
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Atazanavir + rosiglitazone is a combination of two small molecule drugs with distinct mechanisms and indications. Atazanavir is an azapeptide HIV-1 protease inhibitor used in combination with other antiretrovirals for the treatment of HIV-1 infection. It works by selectively inhibiting the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, preventing the formation of mature virions[2][4]. Rosiglitazone is a thiazolidinedione class anti-diabetic agent indicated as an adjunct to diet and exercise to maintain glycemic control in type 2 diabetes mellitus. It acts as a highly selective agonist for peroxisome proliferator activated receptor gamma (PPARγ), enhancing tissue sensitivity to insulin and regulating genes involved in glucose production, transport, and utilization[1][3][6]. There are significant drug-drug interactions between these agents; coadministration may result in elevated plasma concentrations of rosiglitazone due to inhibition of CYP2C8 by atazanavir[5].
- Other names
- atazanavir + rosiglitazone
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)CYP3A (CYP3A family)PR (Progesterone receptor)
Beyond the preview
Go deeper on atazanavir + rosiglitazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atazanavir + rosiglitazone.